International Assets Investment Management LLC Acquires New Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

International Assets Investment Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 13,556 shares of the biotechnology company’s stock, valued at approximately $443,000.

A number of other institutional investors and hedge funds have also modified their holdings of ARWR. Washington Trust Advisors Inc. bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $25,000. Fifth Third Bancorp increased its holdings in shares of Arrowhead Pharmaceuticals by 112.0% in the 3rd quarter. Fifth Third Bancorp now owns 988 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 522 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Arrowhead Pharmaceuticals by 96.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,753 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 1,352 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 130.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,270 shares of the biotechnology company’s stock worth $142,000 after purchasing an additional 2,980 shares in the last quarter. Finally, EP Wealth Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 851.8% in the 3rd quarter. EP Wealth Advisors LLC now owns 8,500 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 7,607 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, CFO Kenneth Allen Myszkowski sold 40,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $35.19, for a total value of $1,407,600.00. Following the sale, the chief financial officer now directly owns 400,600 shares of the company’s stock, valued at $14,097,114. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Christopher Richard Anzalone sold 57,499 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $32.35, for a total value of $1,860,092.65. Following the sale, the chief executive officer now directly owns 3,715,048 shares of the company’s stock, valued at $120,181,802.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kenneth Allen Myszkowski sold 40,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $35.19, for a total value of $1,407,600.00. Following the completion of the sale, the chief financial officer now directly owns 400,600 shares in the company, valued at $14,097,114. The disclosure for this sale can be found here. Insiders own 4.50% of the company’s stock.

Arrowhead Pharmaceuticals Stock Down 6.1 %

NASDAQ:ARWR opened at $21.87 on Friday. The business’s 50-day simple moving average is $28.28 and its two-hundred day simple moving average is $28.88. The stock has a market cap of $2.71 billion, a PE ratio of -7.87 and a beta of 0.71. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $20.67 and a 52 week high of $42.48.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.46). The business had revenue of $3.55 million for the quarter, compared to the consensus estimate of $35.60 million. Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 90.77%. Arrowhead Pharmaceuticals’s revenue was down 94.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.39) earnings per share. Sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ARWR. Bank of America raised their price target on Arrowhead Pharmaceuticals from $29.00 to $37.00 and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Citigroup raised their price target on Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, February 8th. Royal Bank of Canada restated an “outperform” rating and issued a $50.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. Finally, Morgan Stanley raised their price target on Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.45.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.